Phase 3 Readout
Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. O
- Company
- Novo Nordisk A/S (NVO)
- Indication
- Type 2 Diabetes
Other upcoming events for NVO
Phase 3 ReadoutPhase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. O
Phase 3 ReadoutPhase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Par
Phase 2 StartPhase 2 Start: A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes
Phase 3 ReadoutPhase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan
Phase 3 ReadoutPhase 3 Topline: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and A
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.